Nanjing Leads Biolabs' (HKG:9887) biologics license application for LBL-024 was approved for inclusion in priority review and approval procedure by China's National Medical Products Administration.
The drug has been developed as monotherapy for the treatment of advanced extrapulmonary neuroendocrine carcinoma, according to a Friday Hong Kong bourse filing.